The effect of ischemic preconditioning on repeated sprint cycling performance.

STEPHEN D. PATTERSON, NEIL E. BEZODIS, MARK GLAISTER AND JOHN R.

PATTISON

School of Sport, Health and Applied Science, St Mary's University, Strawberry Hill,

Twickenham, TW1 4SX, UK.

Corresponding Author:

Dr Stephen D. Patterson

School of Sport, Health and Applied Sciences

St Mary's University, Twickenham

Waldegrave Road

Strawberry Hill

Twickenham, UK

Phone: +44 2082402357

Fax: +44 2082404212

E-mail: Stephen.Patterson@smuc.ac.uk

Running Title: Ischemic preconditioning and sprint performance

Disclosure of Funding: None

1 Abstract

Purpose: Ischemic preconditioning enhances exercise performance. We tested the hypothesis 2 that ischemic preconditioning would improve intermittent exercise in the form of a repeated 3 sprint test during cycling ergometry. Methods: In a single-blind, crossover study, fourteen 4 recreationally-active males (mean \pm SD; age 22.9 \pm 3.7 years, height 1.80 \pm 0.07 m, mass 5 77.3 ± 9.2 kg) performed twelve 6 s sprints following four 5 min periods of bilateral limb 6 occlusion at 220 mmHg (ischemic preconditioning) or 20 mmHg (placebo). Results: 7 Ischemic preconditioning resulted in a 2.4 \pm 2.2, 2.6 \pm 2.7 and 3.7 \pm 2.4% substantial increase 8 in peak power for sprints 1, 2 and 3 respectively, relative to placebo, with no further changes 9 between trials observed for any other sprint. Similar findings were observed in the first three 10 sprints for mean power output following ischemic preconditioning (2.8 ± 2.5 , 2.6 ± 2.5 and 11 $3.4 \pm 2.1\%$, for sprints 1, 2 and 3 respectively), relative to placebo. Fatigue index was not 12 substantially different between trials. At rest tissue saturation index was not different between 13 trials. During the ischemic preconditioning / placebo stimulus there was a -19.7 \pm 3.6% 14 decrease in tissue saturation index in the ischemic preconditioning trial, relative to placebo. 15 During exercise there was a $5.4 \pm 4.8\%$ greater maintenance of tissue saturation index in the 16 ischemic preconditioning trial, relative to placebo. There were no substantial differences 17 18 between trials for blood lactate, electromyography (EMG) median frequency, oxygen uptake or rating of perceived exertion (RPE) at any time points. Conclusion: Ischemic 19 preconditioning improved peak and mean power output during the early stages of repeated 20 sprint cycling and may be beneficial for sprint sports. 21

22 Key Words: Ischemia, occlusion, power output, multiple sprint, fatigue

24 Introduction

Ischemia-reperfusion injury underpins the damage caused by either disease and /or 25 deliberately imposed interruption of blood supply to tissues. However, since 1986, brief and 26 repeated bouts of ischemia / reperfusion, known as ischemic preconditioning, have been 27 demonstrated to protect many organs, including the myocardium (32), liver (35) and skeletal 28 muscle (21), from the damage caused by a subsequent prolonged ischemic event. In addition 29 to the clinical use of ischemic preconditioning, this technique has also been applied 30 immediately before exercise to improve performance. Across a range of various exercise 31 modes, performance has been enhanced by 1-8% (3, 12, 13, 24, 25) which makes it 32 potentially beneficial for athletic events where such small margins are the difference between 33 winning or losing. 34

Research to date has primarily focussed on events of an endurance nature and has identified 35 improvements in peak oxygen uptake ($\dot{V}O_{2max}$; 13), power output at $\dot{V}O_{2max}$ (12), running 36 time trial performance (3), 1000 m rowing performance (25) and time to task failure (7) 37 following ischemic preconditioning. Relatively little research has focused on performance 38 during shorter durations and the findings are conflicting. For example, an improvement in 39 100 m swimming performance was observed in elite national level swimmers (24) but no 40 effect of ischemic preconditioning was demonstrated on single 30 m running sprint 41 performance (19) or cycling exercise at 130% $\dot{V}O_{2max}$ (12). 42

43 Repeated sprint exercise provides a model to investigate transitions from high to low 44 metabolic work, a common feature of many team sports. The major energy demands of 45 repeated sprint exercise are derived from phosphocreatine (PCr) and anaerobic glycolysis 46 (18), and recent work suggests a strong relationship between PCr resynthesis and recovery of 47 repeated sprint performance (31). Alternatively, there is an increased reliance on aerobic

energy production during the latter stages of repeated intense exercise as evidenced by a larger reduction in anaerobic energy production than performance (18, 30) and increased muscle oxygen uptake (6). Furthermore, reducing (5) or enhancing (4) oxygen availability during repeated exercise impaired or enhanced performance, respectively, which suggests that the aerobic system plays an important role, possibly through faster PCr resynthesis.

Ischemic preconditioning may improve aerobic metabolism as evidenced by increased 53 $\dot{V}O_{2max}$ (13), accelerated $\dot{V}O_2$ kinetics (34) and improved oxygenation of skeletal muscle (38) 54 and it may therefore reduce the performance related decline in power output associated with 55 repeated sprint exercise. Secondly, in ischemic reperfusion injury models, ischemic 56 preconditioning enhances PCr resynthesis following ischemia (1, 29) and thus may enhance 57 the ability to recover between sprints. Therefore, the aim of this study was to investigate the 58 effect of ischemic preconditioning on repeated sprint cycling performance. Given the 59 apparent ability of ischemic preconditioning to improve aerobic metabolism and promote PCr 60 resynthesis it was hypothesized that it would improve repeated sprint cycling performance by 61 reducing the rate of fatigue. 62

63

64 METHODS

65 **Participants**

In a randomized, single blind, crossover study, fourteen healthy males (mean ± standard deviation (SD); age 22.9 ± 3.7 years, height 1.80 ± 0.07 m, mass 77.3 ± 9.2 kg) recreationally active in repeated sprint sports such as field hockey, soccer and rugby, volunteered to participate. Participants were naïve to the effect of ischemic preconditioning on exercise performance and were not informed about the rationale of the study. They were

fully informed of all procedures and associated risks before completing a training history questionnaire and providing written, informed consent. Participants reported they had actively been involved in sport for an average of 12 years, with time spent training each week reported as 6.7 ± 2.3 hours. Approval for the study's procedures was granted by St Mary's University Ethics Committee which conformed to the Declaration of Helsinki.

76 Experimental Overview

All participants reported to the laboratory for four exercise trials. In the initial trial, 77 data were obtained on individual anthropometric characteristics such as body mass, height 78 and four skinfolds (subscapular, biceps brachii, triceps brachii, and iliac crest). During this 79 trial participants were familiarised with the repeated sprint cycling protocol, consisting of 80 81 twelve 6 s cycle sprints with 30 s of passive recovery between each sprint. Trial 2 was a repeat of the first, to further familiarise the participants with the exercise protocol. Trials 3 82 and 4 were the experimental trials which consisted of either ischemic preconditioning or 83 placebo treatment prior to the exercise protocol. The experimental trials were performed in a 84 counterbalanced manner, separated by 5-7 days to ensure no possible carryover of acute 85 86 ischemic preconditioning (28). During both trials respiratory gas exchange, electromyography (EMG) of the vastus lateralis (VL) and near-infrared spectroscopy (NIRS) 87 of the VL were recorded. Participants indicated their rating of perceived exertion (RPE, 6 -88 20: Borg's scale) and blood was taken from the earlobe at rest and following sprints 4, 8 and 89 12 before being subsequently analyzed for lactate. Participants performed all of their trials at 90 the same time of day (±1 h) and laboratory conditions were controlled at approximately 20°C 91 92 and 38% relative humidity during all trials. Participants were instructed to maintain their normal diet, to refrain from any form of intense physical activity and caffeine for the 24 h 93 period prior to testing, and not to eat for 3 h before each trial. 94

95 **Experimental Measures**

96 Ischemic Preconditioning

97 In trials 3 and 4 exercise was preceded by ischemic preconditioning or placebo, performed in a supine position using bilateral occlusion (3, 13). In the ischemic 98 preconditioning trial automatic occlusion cuffs (14.5 cm width - Delfi Medical Innovations, 99 Vancouver, Canada) were positioned proximally around the thigh and inflated to 220 mmHg 100 for 5 minutes followed by 5 minutes of reperfusion. This procedure was repeated four times 101 102 (3). The placebo trial was identical to the ischemic preconditioning trial except that the cuffs were inflated to 20 mmHg. The time delay between the cuff removal and the beginning of the 103 warm up for the exercise test was 30 minutes as ischemic preconditioning has been 104 105 demonstrated to improve exercise performance within 45 minutes of the final cuff inflation (3). 106

107 Repeated-sprint cycling

The exercise protocol consisted of twelve 6 s sprints with resistance set at a torque 108 factor of 1.0 N·m·kg⁻¹ on a cycle ergometer (Lode Excalibur Sport, Groningen, The 109 Netherlands) with individual participant cycling position being established during visit 1 and 110 then replicated on each subsequent visit. Participants performed a standardized warm-up, 111 consisting of 3 minutes of cycling at 120 W, followed by two maximal 6 s sprints, with 1 112 minute between efforts followed by 5 minutes of passive rest. Toe clips were used to secure 113 the feet to the pedals and strong verbal encouragement was provided throughout each trial. 114 Participants performed each sprint with the pedals in the same starting position and were 115 instructed to sprint as fast as possible maintaining maximal effort until asked to stop. Each 116 sprint was initiated by illuminating a series of 20 light emitting diodes (LEDs) which were 117 synchronized with the EMG recording. During the 30 s rest period after each sprint 118

participants remained seated on the ergometer. Mean and peak power output were calculated for each condition. The percentage decrement score (S_{dec}) for all 12 sprints was calculated as the percent difference between total and ideal peak power output, where total power represents the sum of peak power values from all sprints (S_n where n = 1:12) and ideal power represents the number of sprints multiplied by the highest peak power (S_{best}) achieved (20).

124

$$S_{dec}(\%) = \left[1 - \frac{(S_1 + S_2 + \dots S_{12})}{S_{best} \times 12}\right] \times 100$$

125 Cardiorespiratory Measures

Respiratory gas exchange was measured during the entire exercise protocol through 126 breath-by-breath analysis using an open spirometric system (Oxycon Pro, Jaeger, Hoechburg, 127 Germany). The gas analyser was calibrated prior to each trial using oxygen and carbon 128 dioxide gases of known concentrations (Cryoservice, Worcester, UK), and the turbine volume 129 transducer was calibrated using a 3 L precision syringe (Hans Rudolph Inc, Shawnee, USA). 130 131 During the trials participants breathed room air through a facemask (Hans Rudolph, Kansas City, MO, USA) that was secured in place by a head-cap assembly (Hans Rudolph, Kansas 132 City, MO, USA). Respiratory gas exchange data were subsequently averaged on a 1 s basis 133 134 and then averaged for the overall exercise protocol, so that the total time of analysis was 432 s (($12 \times (6 \text{ s sprint} + \text{the following } 30 \text{ s recovery periods})$). 135

136 Muscle EMG

137 The EMG activity of the VL muscle of the right leg was recorded at 1000 Hz using a 138 data acquisition system (Biopac MP150, Biopac Systems Inc. CA, USA). Before placement 139 of the electrodes, the overlying skin was prepared. The hair was shaved and the skin 140 thoroughly cleaned with alcohol to reduce skin electrode interference. Pre-gelled disposable

hypoallergenic 1 cm snap-electrodes (Performance Plus, Vermed, VT, USA) were fixed two-141 thirds of the distance along a line from the anterior spina illaca superior to the lateral side of 142 the patella (17). Electrode centres were placed 2.0 cm apart, parallel to the direction of 143 muscle fibres, with a reference electrode located above a prepared site on the shaft of the 144 tibia. The EMG electrode placement was marked on the skin by indelible pen to ensure 145 similar placement of electrodes between experimental trials. EMG recording was initiated by 146 a digital trigger coincident with the start of each 6 s sprint. The start of each sprint was 147 identified from the square wave pulse provided by the synchronization trigger and the 148 subsequent 6 s of data were used for the analysis of each individual sprint. The raw EMG 149 data were band pass filtered to remove the signal outside of the 20 - 500 Hz range. To 150 investigate the difference in VL EMG frequency between the two conditions, the filtered 151 EMG data from each sprint were transformed in to the frequency domain using a fast Fourier 152 transformation and the median frequency (MDF) of the resulting power spectrum density was 153 calculated. The MDF values from each of the 12 sprints were then analysed using linear 154 regression, and the gradient of this line was extracted as a representation of the change in 155 156 frequency (fatigue) across the 12 sprints (33).

157

158 NIRS Measurements

During experimental trials, muscle oxygenation of the left VL was continuously monitored using portable NIRS apparatus which is a wireless spatially resolved dualwavelength spectrometer (Portamon, Artinis Medical Systems, BV, The Netherlands). Changes in tissue saturation index (TSI, expressed as a %) were measured using two wavelengths (750 and 850 nm), using an arbitrary value for the differential pathlength of 3.83 (10). During rest and prior to the preconditioning procedure a measure of TSI was taken.

165 During the preconditioning and placebo procedures, TSI was averaged over the duration of each 5 minute period of ischemic preconditioning and the value used was for the portion of 166 time the cuff was inflated only (4×5 minutes of pressure). During the repeated sprint cycling 167 protocol, TSI was calculated as an average across all the sprints and recovery time, in a 168 similar manner to oxygen uptake data described above. The NIRS device was positioned on 169 the left VL using the same procedures described above for the EMG placement (for the 170 opposite leg). As with EMG placement an indelible pen was used to mark the placement of 171 the device and to ensure similar placement between trials. The NIRS device was covered with 172 a black light-absorbing cloth to prevent contamination from ambient light. During all tests the 173 NIRS device was connected to a personal computer by Bluetooth for data acquisition (10 174 Hz). Skinfold thickness was measured at the site where the NIRS probe was attached before 175 each trial using Harpenden skinfold calipers (British Indicators Ltd, UK). For all participants, 176 the calculated value of skin and subcutaneous tissue thickness was less than half of the 177 178 distance between the source and the detector.

179 Blood Lactate Measurement

180 The right ear lobe was cleaned using an alcohol swab and punctured using an 181 automated lancet. At rest and immediately following sprints 4, 8 and 12, a blood sample was 182 drawn using a 20 µl capillary tube (EKF Diagnostics, Barleben, Germany). The whole blood 183 sample was hemolysed in a pre-filled micro test tube and analysed using a blood 184 lactate/glucose analyser (Biosen C_Line, EKF Diagnostics, Barleben, Germany).

185 Statistical Analysis

Data were analysed using a contemporary magnitude-based inferences approach (22) because small changes in performance can be meaningful in athletes. Data were log transformed to reduce non-uniformity of error except for RPE due to its interval nature. The

threshold value for the smallest meaningful change for mean and peak power output was set 189 as 0.8% (2). For all other data, the smallest worthwhile or important effect for each 190 dependent variable was the smallest standardised (Cohen) change in the mean: 0.2 times the 191 between-subject SD for baseline values of all participants (8). Qualitative descriptors were 192 assigned to the quantitative percentile scores as follows: 25–75% possible; 75–95% likely; 193 95–99% very likely; >99% almost certain (20). A substantial effect was set at > 75%. Effect 194 size was calculated using threshold values for Cohen's d statistics (0.2; small, 0.5; moderate 195 and 0.8; large). Data are presented as mean \pm SD or percent change from placebo (% $\Delta \pm 90$ %) 196 197 confidence interval (± 90% CI)), percent likelihood that the difference between conditions was larger or smaller (% likelihood) and effect size). An effect was deemed unclear if its 198 confidence limits overlapped the thresholds for both the smallest beneficial and the smallest 199 harmful effect, that is, if the effect could be substantially positive and negative. 200

201

202 **RESULTS**

The maximal peak power (mean \pm SD) obtained during the repeated sprint cycling test was 203 1594 ± 208 and 1630 ± 192 W for placebo and ischemic preconditioning, respectively. 204 Oualitative analysis revealed that performing ischemic preconditioning before sprint activity 205 led to a *likely* increase in maximum peak power output (2.5 \pm 1.9%, 93%, small (% Δ , % 206 likelihood, effect size)). Raw peak and mean power output data for each sprint are presented 207 in Figures 1 and 2, respectively. Ischemic preconditioning, relative to placebo, resulted in 208 substantial increases in peak power output for sprints 1 (2.4 \pm 2.2%, 89% *likely*, small), 2 (2.6 209 \pm 2.7%, 87% likely, small) and 3 (3.7 \pm 2.4%, 97% very likely, small) only, with effects 210 unclear for the remaining sprints. Mean power output followed a similar pattern with 211 substantial increases in sprints 1 (2.8 \pm 2.5%, 91% *likely*, small), 2 (2.6 \pm 2.5%, 88% *likely*, 212

small) and 3 ($3.4 \pm 2.1\%$, 98% *very likely*, small) for the ischemic preconditioning trial, relative to placebo, and the effects on the remaining sprints were deemed unclear. During the repeated sprint cycling protocol, fatigue was evident in both trials as represented by S_{dec} values of $13.2 \pm 5.6\%$ and $14.7 \pm 5.9\%$ for placebo and ischemic preconditioning, respectively. Qualitative analysis revealed a *possibly* greater fatigue rate when repeated sprint cycling was performed following ischemic preconditioning ($13.5 \pm 16\%$, 64% *possible*, small).

Blood lactate was not different at rest prior to the placebo and ischemic preconditioning trials 220 (mean \pm SD; 1.1 \pm 0.2 and 1.0 \pm 0.3 mmol.L⁻¹, respectively; *unclear*, trivial). Blood lactate 221 was *possibly* higher when measured at sprints, 4, 8 and 12 in the ischemic preconditioning 222 (Table 1). Relative to placebo, the effects of ischemic preconditioning on perceived exertion 223 at sprints 4, 8 and 12 were -0.1 ± 0.6 , 0.2 ± 0.7 and 0.1 ± 0.8 (arbitrary units), respectively, 224 with qualitative analysis interpretation deeming differences and effect sizes as unclear or 225 trivial. Data for TSI are presented in Table 1. Briefly, effects for TSI at rest, between trials 226 were unclear. During the occlusion / preconditioning stimulus there was an *almost certain* 227 decrease in TSI during the ischemic preconditioning trial, relative to placebo. During exercise 228 there was a *likely* higher increase in TSI in the ischemic preconditioning trial when compared 229 230 with placebo (Table 1). At rest and during exercise, differences in oxygen uptake between trials were unclear (Table 1). The rate of change in MDF of EMG was *possibly* higher in the 231 ischemic preconditioning trial, relative to the placebo trial (Table 1). 232

233 **DISCUSSION**

The main aim of this study was to investigate the effect of ischemic preconditioning on repeated sprint cycling performance. Relative to placebo, the results showed that ischemic preconditioning was associated with a 2 - 4% increase in both mean and peak power output

in the early phase of the protocol. The improvement in power output is similar to other
ergogenic aids used during this type of exercise (15, 16) and to performance improvements
observed following ischemic preconditioning using different exercise modes (12, 24).

The present investigation is the first to demonstrate an improved power output following 240 ischemic preconditioning during a repeated sprint protocol. Despite rejecting our hypothesis, 241 we did observe substantial increases in both peak and mean power output for the first three 242 sprints. Previous research has demonstrated an improved muscle force production following 243 ischemia and reperfusion in animal (21, 26) and human models (27). Due to the original aim 244 and thus design of the study it was not possible to determine the contribution of increased 245 motor unit recruitment to improved performance, although it does remain a possibility. EMG 246 amplitude has previously been demonstrated to increase in skeletal muscle of animals 247 following ischemic preconditioning (36), suggesting increased motor unit recruitment. In the 248 only relevant human study, muscle fibre conduction velocity, which measures the speed of 249 action potential or excitatory impulse, is increased during isometric exercise; yet ischemic 250 preconditioning did not play a role (37). 251

It is recognized that high energy compounds are important for energy production during 252 repeated sprint activity, with total anaerobic contributions of ATP production during a single 253 6 s sprint being 6%, 50% and 44% from ATP, PCr and anaerobic glycolysis, respectively 254 (18). Whilst speculative, it is possible that the increased power production in the first three 255 sprints in the ischemic preconditioning trial may have been a result of increased ATP 256 production from anaerobic sources. Following ischemic reperfusion injury ATP content is 257 maintained in rabbit and mice heart muscle as a result of ischemic preconditioning via 258 increased concentration of PCr and PCr / ATP ratio (29) or increased anaerobic glycolysis 259 (23). To date little evidence is available on concentrations in skeletal muscle, however 260

increased PCr production has been observed using ³¹P MRS in recovery from an ischemic
event (1). Therefore it is possible that improved power output may be a result of increased
anaerobic energy contribution early in the sprint protocol. Within the current study a *possible*increased blood lactate concentration was observed following the fourth sprint in the
ischemic preconditioning trial, giving further weight to this suggestion although it was not a
substantial effect.

Originally, it was hypothesised that ischemic preconditioning would improve aerobic 267 metabolism and thus improve the ability to recover between sprints. Markers of aerobic 268 fitness such as $\dot{V}O_{2max}$ and $\dot{V}O_2$ kinetic parameters are related to the ability to offset fatigue 269 during a repeated sprint effort (14, 30), whilst an increased aerobic energy production 270 contributes towards power production in the latter stages of repeated intense exercise (6, 18, 271 272 30). Previous research employing one bout of circulatory occlusion prior to the start of an exercise bout has demonstrated accelerated pulmonary $\dot{V}O_2$ kinetics (34). Moreover ischemic 273 preconditioning has been shown to increase $\dot{V}O_{2max}$ (13), suggesting that the method may be 274 used to help maintain power output during repeated sprint exercise, via improved PCr 275 resynthesis (9, 18, 34). However, data from the present study does not support this theory as 276 evidenced by the similarity between trials for \dot{VO}_2 during the repeated sprint protocol. 277

Alongside an increased aerobic metabolism, ischemic preconditioning has been associated with improved muscle oxygenation during and in recovery from exercise (38). As expected, TSI was *almost certainly* decreased by 20% during the preconditioning stimulus, relative to placebo, which is similar to a previous investigation (25). However, during exercise, TSI was *likely* maintained at a higher level in the ischemic preconditioning trial. Since TSI reflects the dynamic balance between O_2 supply and O_2 consumption, the greater TSI observed during the ischemic preconditioning trial is indicative of an improved O_2 delivery at the muscle level

285 (11). This may explain the maintenance of power output in the latter sprints in the ischemic preconditioning condition, despite the higher power outputs early in the trial and place the 286 emphasis on greater O_2 delivery. It should be noted, however, that muscle oxygenation is not 287 a limiting factor during repeated sprint activity (39). Instead, it may be that ischemic 288 preconditioning increases blood flow to skeletal muscle (40), thereby improving power 289 maintenance by increasing microvascular pressure, and/or by increasing metabolite washout 290 (27). However, this mechanism is questionable given that blood flow returns to resting levels 291 within 20 minutes of cuff release (7). 292

Previous research investigating ischemic preconditioning in exercise involving sprint activity 293 has provided conflicting evidence. Elite swimming performance (100 m) is enhanced 294 following ischemic preconditioning (24); however, the time taken to complete the event was 295 ~66 s. thus not typical of a sprint experienced in team sports. Moreover, no effect of ischemic 296 preconditioning has been demonstrated during 'all-out' sprint exercise at 130% $\dot{V}O_{2max}$ or 30 297 m land based sprint running (12, 19). Whilst these results differ from the ones in the current 298 study they may be explained by the timing of the preconditioning strategy. Previous studies 299 have performed a warm up immediately post the preconditioning stimulus and moved straight 300 into the exercise regime (19). In the current study, the warm up was started 30 minutes post 301 the ischemic preconditioning stimulus to make the research more applicable to an athletic 302 setting. Current research investigating performance immediately after the ischemic 303 preconditioning stimulus may be confined to a laboratory setting due to the impracticality of 304 performing a similar action in an athletic event. It may be that the extra recovery time 305 following the ischemic preconditioning stimulus is more beneficial for sprint related activity 306 as demonstrated by the increased power output in the first three sprints. Due to the evidence 307 in a controlled laboratory environment and protocol in the current study, future research 308

should focus on the mechanisms for improved performance and application of ischemicpreconditioning in events which mimic actual performance events.

In conclusion, ischemic preconditioning of skeletal muscle *likely* increases both mean and 311 peak power output in the first three sprints by 2-4% during the early stages of repeated sprint 312 cycling. This was in contrast to our hypothesis that ischemic preconditioning would improve 313 S_{dec} through aerobic metabolism. Moreover S_{dec} was not substantially different between trials, 314 possibly due to maintenance of TSI in the ischemic preconditioning condition. Further 315 research is required to establish the mechanisms for increased power output during repeated 316 sprint cycling following ischemic preconditioning. Overall the results of this study suggest 317 that ischemic preconditioning is a potential aid for improving sprint based performance. 318

319

320 Acknowledgements

321 The authors thank all the participants who volunteered for this study.

322

323 Conflict of Interest

The authors have no conflicts of interest that are relevant to the content of this article. The results of the present study do not constitute endorsement by ACSM

326

327

328

329

330

331

332 **REFERENCES**

- Andreas M, Schmid AI, Keilani M, Doberer D, Bartko J, Crevenna R, Moser E, Wolzt
 M. (2011). Effect of ischemic preconditioning in skeletal muscle measured by
 functional magnetic resonance imaging and spectroscopy: a randomized crossover
- trial. J Cardiovasc Magn Reson. 2011; 13(1): 32
- Argus CK, Driller MW, Ebert TR, Martin DT, Halson SL. The effects of 4 different
 recovery strategies on repeat sprint-cycling performance. *Int J Sports Physiol Perform.* 2013; 8(5): 542-548.
- Bailey TG, Jones H, Gregson W, Atkinson G, Cable NT, Thijssen DH. Effect of
 ischemic preconditioning on lactate accumulation and running performance. *Med Sci Sports Exerc.* 2012; 44(11): 2084-2089.
- Balsom PD, Ekblom B, Sjodin B. Enhanced oxygen availability during high intensity
 intermittent exercise decreases anaerobic metabolite concentrations in blood. *Acta Physiol Scand.* 1994; 150: 455-456.
- 346 5. Balsom PD, Gaitanos GC, Ekblom B, Sjodin B. Reduced oxygen availability during
 347 high intensity intermittent exercise impairs performance. *Acta Physiol Scand.* 1994;
 348 152: 279-285.
- Bangsbo J, Krustrup P, González-Alonso J, Saltin B. ATP production and efficiency
 of human skeletal muscle during intense exercise: effect of previous exercise. *Am J Physiol Endocrinol Metab*, 2001; 280: 956-964.
- 352 7. Barbosa TC, Machado AC, Braz ID, Fernandes IA, Vianna LC, Nobrega AC, Silva
 353 BM. Remote ischemic preconditioning delays fatigue development during handgrip

- The is a non-final version of an article published in final form in Medicine and Science in Sport and Exercise (2015) Aug;47(8):1652-8. doi: 10.1249/MSS.0000000000576
- exercise. *Scand J Med Sci Sports*. 2014; 15. doi: 10.1111/sms.12229. [Epub ahead of
 print].
- Batterham AM, Hopkins W G. Making meaningful inferences about magnitudes. *Int J Sports Physiol Performance* 2006; 3(4): 547-557
- Bogdanis GC, Nevill ME, Boobis LH, Lakomy HK. Contribution of phosphocreatine
 and aerobic metabolism to energy supply during repeated sprint exercise. *J Appl Physiol.* 1996; 80(3): 876-884.
- 361 10. Buchheit M , Bishop D , Haydar B, Nakamura FY, Ahmaidi S. Physiological
 362 Responses to Shuttle Repeated-Sprint Running. *Int J Sports Med.* 2010; 31(6): 402363 409.
- 364 11. Buchheit M, Ufland P. Effect of endurance training on performance and muscle
 365 reoxygenation rate during repeated-sprint running. *Eur J Appl Physiol.* 2011; 111(2):
 366 293-301.
- 12. Crisafulli A, Tangianu F, Tocco F, Concu A, Mameli O, Mulliri G, Caria MA.
 Ischemic preconditioning of the muscle improves maximal exercise performance but
 not maximal oxygen uptake in humans. *J Appl Physiol*. 2011; 111(2): 530-6.
- 13. de Groot PC, Thijssen DH, Sanchez M, Ellenkamp R, Hopman MT. Ischemic
 preconditioning improves maximal performance in humans. *Eur J Appl Physiol*. 2010;
 108(1): 141-6.
- 373 14. Dupont G, Millet GP, Guinhouya C, Berthoin S. Relationship between oxygen uptake
 374 kinetics and performance in repeated running sprints. *Eur J Appl Physiol* 2005; 95(1):
 375 27-34.
- 376 15. Faulkner SH, Ferguson RA, Gerrett N, Hupperets M, Hodder SG, Havenith G
 377 Reducing muscle temperature drop after warm-up improves sprint cycling
 378 performance. *Med Sci Sports Exerc.* 2013; 45(2): 359-365.

- The is a non-final version of an article published in final form in Medicine and Science in Sport and Exercise (2015) Aug;47(8):1652-8. doi: 10.1249/MSS.000000000000576
- 379 16. Foster J, Taylor L, Chrismas BC, Watkins SL, Mauger AR. The influence of
 380 acetaminophen on repeated sprint cycling performance. *Eur J Appl Physiol*. 2014;
 381 114(1): 41-8.
- 17. Freriks B, Hermens H, Disselhorst-Klug C, Rau G. The recommendations for sensors
 and sensor placement procedures for surface electromyography. In: Hermens H,
 Freriks B, Merletti R, Stegeman D, Blok J, Rau G, et al., editors. European
 recommendations for surface electromyography. Enschede (The Netherlands):
 Roessingh Research and Development BV; 1999. p. 15–54.
- 387 18. Gaitanos GC, Williams C, Boobis LH, Brooks S. Human muscle metabolism during
 388 intermittent maximal exercise. *J Appl Physiol*.1993; 75: 712–719.
- 389 19. Gibson N, White J, Neish M, Murray A. Effect of ischemic preconditioning on land390 based sprinting in team-sport athletes. *Int J Sports Physiol Perform*. 2013; 8(6): 671391 676.
- 392 20. Glaister M, Stone MH, Stewart AM, Hughes M, Moir GL. The reliability and validity
 393 of fatigue measures during short-duration maximal-intensity intermittent cycling. J
 394 Strength Cond Res. 2004; 18(3): 459–62.
- 395 21. Gürke L, Marx A, Sutter PM, Frentzel A, Salm T, Harder F, Seelig J, Heberer M.
 396 Ischemic preconditioning improves postischemic skeletal muscle function. *Am. Surg.*397 1996; 62: 391–394.
- 398 22. Hopkins WG, Marshall SW, Batterham AM, Hanin J. Progressive statistics for studies
 399 in sports medicine and exercise science. *Med Sci Sports Exerc.* 2009; 41(1): 3–13.
- 400 23. Janier MF, Vanoverschelde JL, Bergmann SR. Ischemic preconditioning stimulates
 401 anaerobic glycolysis in the isolated rabbit heart. *Am J Physiol*. 1994; 267(4):H1353-
- 402

60.

24. Jean-St-Michel E, Manlhiot C, Li J, Tropak M, Michelsen MM, Schmidt MR,

McCrindle BW, Wells GD, Redington AN. Remote preconditioning improves
maximal performance in highly trained athletes. *Med Sci Sports Exerc.* 2011; 43(7):
1280-1286.

403

- 407 25. Kjeld T, Rasmussen MR, Jattu T, Nielsen HB, Secher NH (2014). Ischemic
 408 preconditioning of one forearm enhances static and dynamic apnea. *Med Sci Sports*409 *Exerc.* 2014; 46(1):151-155.
- 410 26. Lawson CS, Downey JM. Preconditioning: state of the art myocardial protection.
 411 *Cardiovasc Res.* 1993; 27(4): 542-50.
- 412 27. Libonati JR, Howell AK, Incanno NM, Pettee KK, Glassberg HL. Brief muscle
 413 hypoperfusion/hyperemia: an ergogenic aid? *J Strength Cond Res.* 2001; 15(3): 362-6.
- Loukogeorgakis SP, Panagiotidou AT, Broadhead MW, Donald A, Deanfield JE,
 MacAllister RJ. Remote ischemic preconditioning provides early and late protection
 against endothelial ischemia-reperfusion injury in humans: role of the autonomic
 nervous system. *J Am Coll Cardiol.* 2005; 46(3): 450–456.
- 29. Lukes DJ, Lundgren A, Skogsberg U, Karlsson-Parra A, Soussi B, Olausson M.
 Ischemic Preconditioning Can Overcome the Effect of Moderate to Severe Cold
 Ischemia on Concordant Mouse Xeno–Heart Transplants. *Transplant Proc.* 2005;
 37(8):3332-4.
- 30. McGawley K, Bishop DJ. Oxygen uptake during repeated-sprint exercise. *J Sci Med Sport.* 2014 Feb 10. pii: S1440-2440(14)00030-9. doi: 0.1016/j.jsams.2014.02.002.
 [Epub ahead of print.
- 31. Mendez-Villanueva A, Edge J,Suriano R, Hamer P, Bishop D. The Recovery of
 Repeated-Sprint Exercise Is Associated with PCr Resynthesis, while Muscle pH and
 EMG Amplitude Remain Depressed. *PLOS One*. 2012; 7(12): e51977

- The is a non-final version of an article published in final form in Medicine and Science in Sport and Exercise (2015) Aug;47(8):1652-8. doi: 10.1249/MSS.00000000000576
- 32. Murry, CE, Jennings RB, Reimer KA. A delay in lethal cell injury in ischemic
 myocardium. *Circulation*. 1986; 74(5): 1124-1136.
- 33. Ng JKF, Richardson CA, Kippers V, Parnianpour M, Bui BH. Clinical applications of
 power spectral analysis of electromyographic investigations in muscle tension. *Manual Therapy*. 1996; 2: 99-103.
- 34. Paganelli W, Pendergast DR, Koness J, Cerretelli P. The effect of decreased muscle
 energy stores on the VO2 kinetics at the onset of exercise. *Eur J Appl Physiol Occup Physiol. 1989*; 59: 321–326
- 35. Pang CY, Yang RZ, Zhong A, Xu N, Boyd B, Forrest CR. Acute ischaemic
 preconditioning protects against skeletal muscle infarction in the pig. *Cardiovasc Res.*1995; 29(6): 782–788.
- 36. Phillips, D.J., Petrie, S.G., Zhou, B.-H., Guanche, C.A., and Baratta, R.V. Myoelectric
 and mechanical changes elicited by ischemic preconditioning in the feline hindlimb. *J. Electromyogr. Kinesiol.* 1997; 7(3): 187–192.
- 37. Rongen GA, van Dijk JP, van Ginneken EE, Stegeman DF, Smits P, Zwarts MJ
 Repeated ischaemic isometric exercise increases muscle fibre conduction velocity in
 humans: involvement of Na(+)-K(+)-ATPase, *J Physiol*. 2002; 540(3): 1071-8.
- 38. Saito T, Komiyama T, Aramoto H, Miyata T, Shigematsu H. Ischemic
 Preconditioning Improves Oxygenation of Exercising Muscle in Vivo. *J Surg Res.*2004; 120(1): 111-8.
- 39. Smith KJ, Billaut F. Influence of cerebral and muscle oxygenation on repeated-sprint
 ability. *Eur J Appl Physiol*. 2010; 109(5): 989-99.

The is a non-final version of an article published in final form in Medicine and Science in • Sport and Exercise (2015) Aug;47(8):1652-8. doi: 10.1249/MSS.000000000000576 40. Wang WZ, Stepheson LL, Fang XH, Khiabani KT, Zamboni WA. Ischemic preconditioning-induced microvascular protection at a distance. J Reconstr Microsurg 2004; 20: 175–181.

470

471

472 Figure Legends

473 Figure 1. Peak power output data during twelve maximal 6 s sprints following ischemic
474 preconditioning (solid bars) or placebo (open bars). Data are mean ± SD. * indicates
475 substantially different from placebo (> 75% likelihood).

Figure 2. Mean power output data during twelve maximal 6 s sprints following ischemic preconditioning (sold bars) or placebo (open bars). Data are mean \pm SD. * indicates substantially different from placebo (>75% likelihood).

479 Table Legends

480 Table 1. Statistical summary of the differences between ischemic preconditioning and 481 placebo for oxygen uptake, tissue saturation index, EMG, and blood lactate.



Figure 1.



Figure 2.

	Placebo	Ischemic preconditioning	Mean Change ^a ; ± 90% CI (%)	Qualitative Inference ^b (% Likelihood)	Effect Size (Qualitative Descriptor)
\dot{VO}_2 Rest (L.min ⁻¹)	0.4 ± 0.1	0.4 ± 0.1	1.9 ± 15.6	Unclear	0.08 (trivial)
VO₂ Exercise (L.min ⁻¹)	2.6 ± 0.3	2.7 ± 0.4	4.3 ± 7.3	Unclear	0.29 (small)
TSI Rest (%)	71.8 ± 5.1	73.0 ± 4.0	1.7 ± 3.6	Unclear	0.24 (small)
TSI Occlusion (%)	72.3 ± 5.5	58.0 ± 4.2	-19.7 ± 3.6	Almost Certainly decreased (100%)	2.77 (Large)
TSI Exercise (%)	57.7 ± 5.0	60.9 ± 6.0	5.4 ± 4.8	Likely Increased (93%)	0.56 (Moderate)
Rate of change in EMG MDF (Hz/sprint)	-0.04± 0.43	-0.28 ± 0.42	48.9 ± 69.7	Possibly Higher (73%)	0.37 (small)
Sprint 4 Blood Lactate (mmol.L ⁻¹)	6.9 ± 2.1	7.5 ± 2.3	7.1 ± 11.4	Possibly Higher (50%)	0.19 (trivial)
Sprint 8 Blood Lactate (mmol.L ⁻¹)	9.6 ± 2.8	10.2 ± 2.3	4.3 ± 6.4	Possibly Higher (25%)	0.12 (trivial)
Sprint 12 Blood Lactate (mmol.L ⁻¹)	11.1 ± 3.5	11.8 ± 2.7	5.5 ± 6.4	Possibly Higher (26%)	0.13 (trivial)

Table 1.

90% CI = 90% confidence interval

a Mean change refers to ischemic preconditioning minus placebo trial.

b Inference about the magnitude of the effect

Bold inferences (% likelihood) indicate conditions with substantial change (> 75% likelihood).